Becton Dickinson and Company

$169.54
(as of May 1, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Becton Dickinson and Company

Stock Price
$169.54
Ticker Symbol
BDX
Exchange
NYSE

Industry Information for Becton Dickinson and Company

Sector
Healthcare
Industry
Medical Instruments & Supplies

Company Description for Becton Dickinson and Company

Country
USA
Full Time Employees
70,000

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Fundamentals for Becton Dickinson and Company

Market Capitalization
$58,756,440,064
EBITDA
$5,496,000,000
Dividends per Share
$3.89
P/E Ratio
34.39
Forward P/E Ratio
14.77
Earnings per Share
$5.95
Earnings per Share Estimate Next Year
Profit Margin
8.37%
Shares Outstanding
287,135,008
Percent Owned by Insiders
0.56%
Percent Owned by Institutions
93.77%
52-Week High
52-Week Low

Technical Indicators for Becton Dickinson and Company

50-Day Moving Average
200-Day Moving Average
RSI
21.67
7.87

Analyst Ratings for Becton Dickinson and Company

Strong Buy
8
Buy
5
Hold
4
Sell
0
Strong Sell
0

News About Becton Dickinson and Company

May 1, 2025, 1:27 PM EST
Check out the companies making headlines in midday trading: Meta Platforms — Shares of the Facebook parent jumped about 4% after the company beat earnings expectations . See more.
May 1, 2025, 12:06 PM EST
VCG / VCG via Getty Images See more.
May 1, 2025, 11:39 AM EST
Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.35 in the second quarter of fiscal 2025, up 5.7% year over year. See more.
May 1, 2025, 9:30 AM EST
For the quarter ended March 2025, Becton Dickinson (BDX) reported revenue of $5.27 billion, up 4.5% over the same period last year. See more.